Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: A randomized phase II study of S-1 monotherapy versus cisplatin with vinorelbine for completely resected stage II/IIIA non-small cell lung cancer: rationale and study protocol design for the LOGIK1702 study

Fig. 2

Treatment schedule and outcome measures of arm A (2A) and arm B (2B). ●; Measurements, ▲; Measurable facilities (Once a month), △; optional. *1; Measurements at every 90 (±30) days until 3 years from the start of the treatment. Every 180 (±60) days thereafter.*2; Measurements at every 180 (±60) days until 3 years from the start of the treatment. Every 365 (±90) days thereafter. *3: Measurements at 365 (±60) days and 545(±60) days. CT Computed tomography, MRI Magnetic resonance imaging, RI Radio isotope, PET Positron emission tomography, WPAI Work productivity and activity impairment questionnaire

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us